2. ) contains a link and an image, which is the website’s logo.
Article Content:
Headline/Title: the paper title is not directly present in the snippet, but it’s referenced within the article’s content.
Source Information:
Healthcare Economist June 23, 2025Jason Shafrin
Paper Link and Abstract: The article presents a link to a “paper out today in the Journal of Comparative Effectiveness Research” along with a quoted abstract from the paper. the abstract discusses a cost-saving analysis of different Bruton’s tyrosine kinase inhibitors (cBTKi) for treating chronic lymphocytic leukemia (CLL) from a Medicare outlook. Advertisements: The code includes placeholders and links for advertisements (“ramaonhealthcare – Advertise With Us,” “Venturous,” “ZeOmega”). The ads are responsive, with different versions displayed on tablets and mobile devices.
Topics: Links to categories related to the article’s content: “Insurance,” “Medicare.”
Sidebar:
Contains widgets defined inside tags.
Important Points:
Dynamic Content: This is likely dynamically generated HTML. In WordPress (or similar systems), the content of the article, the advertisement URLs, and other elements are populated from a database or CMS.
CSS Styling: The inline styles (style=”…”) and the block at the end indicate that CSS is being used to control the visual presentation of the page.
JavaScript: There may be associated JavaScript code, not present in this snippet, that handles interactivity (e.g., modal behaviour, ad tracking).
Responsiveness: The use of img-responsive class suggests the site is designed to adapt to different screen sizes.
Accessibility: The code uses aria-label and aria-hidden attributes to improve accessibility for users with disabilities.
Future date: The post date is “June 23, 2025” which suggests this content might be pre-written or part of a exhibition.
this is the HTML markup for a blog post on a healthcare-related website,featuring an article about the cost-effectiveness of different leukemia treatments,alongside advertisements and links to relevant topics. Here are a few PAA (People Also Ask) related questions for the provided article, each on a new line:
BTKi Cost in Medicare CLL Patients: A Comprehensive Guide
BTKi Cost in Medicare CLL Patients: Navigating Treatment Expenses
Managing the cost of chronic lymphocytic leukemia (CLL) treatment,particularly when using Bruton’s tyrosine kinase inhibitors (BTKis),can be a notable concern for Medicare beneficiaries. This article provides a detailed overview of BTKi costs, Medicare coverage, and strategies for managing expenses. We’ll delve into the specifics of BTKi cost, Medicare coverage for CLL, and financial assistance options.
Understanding BTKi Medications and Their Costs
Bruton’s tyrosine kinase inhibitors (BTKis) are a class of targeted therapies that have revolutionized the treatment of CLL. These medications work by inhibiting the BTK enzyme,which plays a crucial role in the survival and proliferation of CLL cells. Common BTKis include:
Ibrutinib (Imbruvica)
acalabrutinib (Calquence)
Zanubrutinib (Brukinsa)
The BTKi medications mentioned above are very effective, increasing patient survival and overall quality of life. However, they come with a substantial price tag. The cost of BTKi can range significantly depending on the specific medication, dosage, and insurance coverage.
Factors Influencing BTKi Costs
